text
stringlengths 0
197k
|
|---|
Patients may receive up to 2 cycles of treatment spaced 24 weeks apart. conditions: Lupus Nephritis - WHO Class III conditions: Lupus Nephritis - WHO Class IV studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: AB-101 name: Cyclophosphamide name: Fludarabine name: Rituximab measure: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events measure: AB-101 Clinical Activity sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California, San Diego status: RECRUITING city: San Diego state: California zip: 92121 country: United States name: Bosco Trinh role: CONTACT name: Bethany Karl, DO role: PRINCIPAL_INVESTIGATOR lat: 32.71533 lon: -117.15726 hasResults: False
|
<|newrecord|> nctId: NCT06265207 id: ArdahanU-Simsekli-DS-02 briefTitle: The Effect of Virtual Reality on Pain, Anxiety and Satisfaction Level Before Mammography overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-03-15 date: 2025-04-15 date: 2024-02-20 date: 2024-02-20 name: Ardahan University class: OTHER name: Kafkas University briefSummary: In this study, it is planned to determine the effect of virtual reality applied to women before mammography on pain, anxiety and satisfaction levels. For this purpose, individuals applying for breast cancer screening will first be randomly divided into experimental and control groups. Pain, anxiety and satisfaction level evaluation forms will be applied to the experimental group before the mammography procedure. A relaxing video will be watched with virtual reality glasses and the mammography will be performed. At the end of the mammography, the relevant forms will be applied to the individuals again. The control group will not be subjected to any additional application that will continue with the applied routine. conditions: Mammography conditions: Early Diagnosis of Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single Blind Parallel Group Randomized Controlled Trial primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Since the researcher will be conducting the research, blinding will not be possible, and separate consent forms were prepared for the experimental and control groups, without specifying which group they were in, and it was planned to blind the participants in this way. In addition, in order to prevent statistical bias, it is planned to prevent bias in data analysis by coding the data as first group and second group, rather than experimental and control group, when entering the data into SPSS, and by not giving information about which group is the experiment and which is the control group. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 78 type: ESTIMATED name: Virtual reality name: routine maintenance measure: Visual Comparison Scale measure: State Anxiety Inventory measure: Satisfaction Evaluation Scale sex: FEMALE minimumAge: 18 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06265194 id: ZAT2024 briefTitle: Effect of EMDR in the Treatment of Fibromyalgia acronym: EMDR overallStatus: COMPLETED date: 2015-01-01 date: 2018-01-01 date: 2018-03 date: 2024-02-20 date: 2024-02-20 name: Academy of Therapeutic Sciences, Turkey class: OTHER briefSummary: The goal of this randomized-controlled study is to investigate the impact of EMDR therapy on fibromyalgia symptoms, depression, sleep quality, and traumatic stress in fibromyalgia patients.
|
The main questions it aims to answer are:
|
* Does EMDR become useful in relieving pain and complaints in fibromyalgia patients?
|
* Is specific EMDR Fibromyalgia Protocol effective of fibromyalgia patients?
|
* Does EMDR therapy decrease depression, sleep quality and traumatic stress symptoms of individuals with fibromyalgia? conditions: Fibromyalgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Eligible participants were randomized into two groups: one receiving TAU treatment (control group) and the other receiving both TAU and EMDR (experimental group). primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants do not have the knowledge of group interventions. whoMasked: PARTICIPANT count: 79 type: ACTUAL name: EMDR name: TAU measure: Fibromyalgia Impact Questionnaire (FIQ) measure: Pittsburgh Sleep Quality Index (PSQI) measure: Trauma Symptom Checklist-40 (TSC-40) measure: Beck Depression Inventory (BDI) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06265181 id: AIBU-SBF-SK-04 briefTitle: The Effect of Diabetes Coaching on Distress and Diabetes Self-Management overallStatus: NOT_YET_RECRUITING date: 2024-03-27 date: 2026-12-31 date: 2027-12-31 date: 2024-02-20 date: 2024-02-20 name: Abant Izzet Baysal University class: OTHER briefSummary: This research is a randomized controlled, experimental study planned to evaluate the effect of diabetes coaching on diabetes self-management, glycosylated hemoglobin and diabetes distress levels in individuals with type 2 diabetes.
|
The research is planned to start on 01.01.2024. Participants will be divided into experimental and control groups using the block randomization method. Participants in the experimental group will first receive 8 sessions of diabetes coaching every 10 days after the chemistry interview. No intervention will be made to the control group. The preliminary implementation of the research will be carried out with 4 individuals with diabetes who voluntarily accept participation and meet the inclusion criteria. Data will be collected by face-to-face interview method. Data will be analyzed with IBM SPSS V23 program. conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Experimental and control group. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: When the researcher evaluates the participant according to the inclusion criteria, written consent will be obtained from the participant and pre-evaluation forms will be applied when compliance with the criteria is achieved. Afterwards, the participant's group will be notified to the researcher by the independent researcher and randomization will be carried out. With this; Data entries will be made by an independent researcher as group A and group B, without writing the group names. Until the data analysis and reporting is completed, the statistician will be blinded to which group is the intervention and which group is the control. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 64 type: ESTIMATED name: Diabetes coaching measure: Type 2 Diabetes Self-Management Scale measure: Diabetes Distress Scale measure: HbA1c Monitoring Form measure: Introductory Features Form sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06265168 id: req-2023-01512; am23Sutter3 briefTitle: Comprehensive Observations and Multidisciplinary Approaches in the Management of Unconscious Patients acronym: COMA overallStatus: RECRUITING date: 2024-03-01 date: 2026-12-31 date: 2026-12-31 date: 2024-02-20 date: 2024-04-11 name: University Hospital, Basel, Switzerland class: OTHER briefSummary: This prospective observational high-fidelity simulation study aims to observe and better understand how physicians from different disciplines differentiate in the management of a comatose patient and how their diagnostic and treatment approaches adhere to current recommendations in a highly standardized simulated scenario. The results gained by this study will give more insight into the current quality of diagnostic procedures and treatment and help refine recommendations in this context. The investigators hypothesize that physicians do not strictly adhere (regarding diagnostic approach and treatment) to current guidelines/recommendations when confronted with a comatose patient. conditions: Coma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Simulation measure: To reveal diagnostic and treatment approaches of physicians from different disciplines when confronted with a comatose patient. measure: Physicians' grade of adherence to current recommendations regarding diagnostic procedures and treatment of a comatose patient measure: Participants' self-evaluation of their performance in hindsight sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Basel status: RECRUITING city: Basel country: Switzerland name: Prof. Dr. Sutter role: CONTACT name: Liliane Nueesch role: CONTACT lat: 47.55839 lon: 7.57327 hasResults: False
|
<|newrecord|> nctId: NCT06265155 id: SuzhouMHAnhui briefTitle: Triggers of Acute Ischemic Stroke Due to Large Vessel Occlusion overallStatus: RECRUITING date: 2024-02-01 date: 2025-06-30 date: 2025-12-31 date: 2024-02-20 date: 2024-03-28 name: Anzhi Li class: OTHER briefSummary: Acute ischemic stroke has a high incidence, ischemic stroke caused by large vessel occlusion is serious and has a poor prognosis, and its triggers in the short term before onset are not clear. The aim of this study was to evaluate the short-term risk of acute ischemic stroke caused by multiple triggers. In this trial, through a case-crossover study design, patients were asked about the exposure to each trigger in the previous year and the exposure during the preictal risk period (the exposure observed during the risk period) for each potential trigger of acute ischemic stroke caused by large vessel occlusion. To evaluate the relative risk of ischemic stroke resulting from exposure to triggers, comparing exposure during the dangerous period with the usual frequency of exposure. Relative risks and corresponding 95% CIs were estimated for past-year exposure and past-year mean exposure (assessed as chronic risk factors) and time to last exposure (assessed as triggers). Scientifically evaluate exposure to a range of potential triggers, including infection, mood, smoking, alcohol consumption, diarrhea and vomiting, extreme temperature changes, and several factors that increase blood pressure and their risk of developing acute ischemic stroke. conditions: Triggers of Acute Ischemic Stroke Due to Large Vessel Occlusion studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 302 type: ESTIMATED measure: RR values for exposure during the risk period versus exposure in the past year for each trigger sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Suzhou Hospital Anhui Medical University status: RECRUITING city: Suzhou state: Anhui zip: 234000 country: China name: Anzhi Li, B.S. role: CONTACT phone: +8615903860581 email: 365819805@qq.com name: Zhengfei Ma, M.D. role: CONTACT phone: 13866586362 email: Zhengfeima@126.com lat: 31.30408 lon: 120.59538 hasResults: False
|
<|newrecord|> nctId: NCT06265142 id: MoH/CSR/23/26368 briefTitle: Clean Catch Urine Feasibility and Contamination Rate Compared to Bladder Catheterization Urine in Pre-Continent Children overallStatus: NOT_YET_RECRUITING date: 2024-02-15 date: 2024-09-01 date: 2024-12-01 date: 2024-02-20 date: 2024-02-20 name: Oman Medical Speciality Board class: OTHER_GOV briefSummary: Introduction: Urinary tract infections (UTIs) are a common source of infection in children, accounting for a significant proportion of visits every year. Diagnosing UTIs requires obtaining a urine specimen, which can be collected using four methods: invasive techniques, such as suprapubic aspiration and urethral bladder catheterization, and noninvasive techniques, such as sterile bag and clean catch. However, catheterization can be a painful and invasive procedure, particularly in young infants who are less cooperative, and sometimes tends to be rejected by parents.
|
Given the availability of alternative methods with comparable contamination rates, we aim to investigate the feasibility and contamination rate of clean catch urine compared to bladder catheterization, as well as secondary outcomes such as pain scores, parental satisfaction, and time required to collect urine for each technique.
|
Methods: To achieve this, we will conduct a randomized control trial in precontinent pediatric patients. A pilot study with 40 samples in each arm will be conducted since there is no prior information about contamination rates in our setting. A well-designed and labeled data collection sheets will be used for data collection, and the data will be entered using EPI-data software. Statistical analysis will be performed using IBM SPSS statistics.
|
Aim: The main aim of this study is to introduce clean catch urine (bladder massage technique) to our setting, and to compare its feasibility with the bladder catheterization which is the standard practice.
|
Patient Population: young infants from 0 to 6 months of age
|
Intervention: There will be two groups:
|
1. Group A (Experimental group):Urine samples will be collected using the clean catch urine method (bladder massage technique).
|
2. Group B (Control group): Urine samples will be collected using the standard bladder catheterization method.
|
Clinical Measurement: All collected urine samples will be labeled and sent to the laboratory. All results will be retrieved from the medical records. Direct measurement will be for the duration of the procedures in both experiment and control group (stopwatch will be used). Pain score (Neonatal Infant Pain Scale) and parental satisfaction survey will be filled at the time of the procedure.
|
Outcome: Contamination rate and feasibility of both urine sampling techniques conditions: Urinary Tract Infections studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patient will be assessed in triage and cases to be included in the study as per the inclusion criteria, after that patients will be randomized using computerized block randomization technique into two groups. Then, patients will be assigned to a bed, pulse oximetry to be applied, data collection sheet to be filled, confirm that infant had good feeding/ didn't pass urine over last 20 minutes and proper cleaning to be done. The next step will be, collecting urine sample according to randomization group. Group A patients (control group), urine to be collected by standardized catheterization technique while group B by standard CCU technique. Meanwhile, time of each procedure to be documented. Regarding group B , after collecting urine by CCU , we recommend to collect another sample by catheterization to guide the management and antibiotic choice. primaryPurpose: DIAGNOSTIC masking: SINGLE maskingDescription: The statistician who will analyze the data will be blinded. whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Bladder catheterization name: clean catch urine via bladder massage technique measure: Urine culture contamination rate measure: Parental satisfaction questionnaire measure: duration of the procedure measure: Pain score sex: ALL minimumAge: 1 Day maximumAge: 6 Months stdAges: CHILD typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-01-01 uploadDate: 2024-02-14T09:44 filename: Prot_000.pdf size: 662911 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-01-01 uploadDate: 2024-02-14T09:45 filename: ICF_001.pdf size: 128074 hasResults: False
|
<|newrecord|> nctId: NCT06265129 id: R.23.12.2429 briefTitle: The Association Between Obstructive Sleep Apnea Severity and Red Blood Cells Indices overallStatus: COMPLETED date: 2023-03-20 date: 2023-10-20 date: 2023-12-20 date: 2024-02-20 date: 2024-02-20 name: Mansoura University class: OTHER briefSummary: Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of obstructive events (apnea and hypopnea) and intermittent hypoxia, which in turn contributes to the systemic inflammation that underlies this disease and its consequences (Ryan et al 2009, Gileles-Hillel et al 2014). This systemic inflammation leads to endothelial dysfunction, which contributes to the pathogenesis of cardiovascular complications in OSAS, in addition to the exposure to risk factors, such as male gender, older age, obesity, and lack of exercise (Lorenzi Filho et al 2010). Some red blood cells (RBC) and platelets indices have emerged as inflammatory biomarkers in various diseases (Tertemiz et al 2016) The severity of OSA is significantly associated with increase hematocrit, even after controlling for possible confounding variables. However, nocturnal hypoxemia in OSA does not usually lead to clinical polycythemia (Choi et al 2006). In patients referred with a clinical diagnosis of OSAS, RDW may be a marker for the severity of the condition. As RDW is usually included in a complete blood count, it could provide an inexpensive tool for triaging OSAS patients for polysomnography evaluation (Sökücü et al 2012). The hematological indices white blood cell count (WBC), neutrophil count, lymphocyte count, mean platelet volume (MPV), platelet distribution width (PDW), and red blood cell distribution width (RDW) have been proposed as alternative markers to those normally used clinically, e.g., interleukin-6 (IL6) and C-reactive protein, to evaluate the burden of inflammation in OSAS (Wu et al 2018) conditions: Obstructive Sleep Apnea studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 30 type: ACTUAL name: Complete blood picture (done in the morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW) measure: Red Blood Cells Indices sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tamer Awad Elsayed city: Mansoura state: Dakhlia zip: 050 country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
|
<|newrecord|> nctId: NCT06265116 id: A0801024 CD briefTitle: One-Step Universal Adhesives: A 3-year Clinical Trial in Class II Composite Restorations overallStatus: RECRUITING date: 2024-01-23 date: 2027-01-23 date: 2027-01-30 date: 2024-02-20 date: 2024-02-20 name: Mansoura University class: OTHER briefSummary: to evaluate and compare the clinical performance and periodontal responses of four commercially available one-step universal adhesives with different formulations in Class II composite restorations over a three-year period. conditions: Dental Caries Class II conditions: Marginal Integrity of Composite Restorations With Universal Adhesives studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: One-step universal adhesive measure: Percentage of functional and biological properties for each group sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: Omar Abd El-Fattah Abd El-Maksoud status: RECRUITING city: Mansoura state: Dakahlia zip: 35516 country: Egypt name: Omar A Abd El-Maksoud role: CONTACT phone: 01024366555 email: omarabdelfata7.92@gmail.com lat: 31.03637 lon: 31.38069 hasResults: False
|
<|newrecord|> nctId: NCT06265103 id: 20190407 briefTitle: Epilepsy Learning Healthcare System (ELHS) acronym: ELHS overallStatus: RECRUITING date: 2019-03-20 date: 2099-02-14 date: 2099-02-14 date: 2024-02-20 date: 2024-02-20 name: Epilepsy Foundation of America class: OTHER briefSummary: The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy. The ELHS is designed as a model of value-based chronic care for epilepsy as envisioned by the National Academies of Medicine Committee in their landmark reports "The Learning Health System" and "Epilepsy Across the Spectrum: Promoting Health and Understanding".
|
The ELHS network is a collaboration among clinicians, patients and researchers that promotes the use of data for multiple purposes including one-on-one clinical care, population management, quality improvement and research. The ELHS Registry includes data on children and adults with epilepsy collected during the process of standard epilepsy care. These data are used to create population health reports and to track changes in outcomes over time. ELHS teams use quality improvement methods, such as Plan-Do-Study-Act (PDSA) cycles, to continuously learn how to improve care. conditions: Epilepsy conditions: Seizure Disorder conditions: Neurologic Disorder conditions: Rare Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 1000 type: ESTIMATED name: Clinical care and quality improvement measure: Seizure Frequency measure: Seizure Freedom measure: Quality of Life documentation sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Barrow Neurological Institute Comprehensive Epilepsy Center status: RECRUITING city: Phoenix state: Arizona zip: 85013 country: United States name: Malinda Brooks-Busch, MPH role: CONTACT phone: 602-406-3443 email: Malinda.Brooks-Busch@dignityhealth.org name: Sue Herman, MD role: PRINCIPAL_INVESTIGATOR lat: 33.44838 lon: -112.07404 facility: University of Southern California status: RECRUITING city: Los Angeles state: California zip: 90032 country: United States name: Alissa Maier, MPH role: CONTACT phone: 937-545-2627 email: Alissa.Maier@med.usc.edu name: Christi Heck, MD role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 facility: Epilepsy Foundation status: RECRUITING city: Bowie state: Maryland zip: 20716 country: United States name: Kathleen Farrell, MB BCh BAO role: CONTACT phone: 732-832-5983 email: kfarrell@efa.org name: Saniya Griffin role: CONTACT email: elhs@efa.org name: Brandy Fureman, Ph.D role: PRINCIPAL_INVESTIGATOR lat: 38.94278 lon: -76.73028 facility: Partners - Massachusetts General Hospital Epilepsy Service (MGH)/ Partners - Brigham and Women's (BWH) status: RECRUITING city: Boston state: Massachusetts zip: 02114 country: United States name: Jason Raymond Smith role: CONTACT phone: 617-726-3311 email: JSMITH114@PARTNERS.ORG name: Daniel Hoch, MD, Ph.D role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Beth Israel Deaconess Medical Center's Comprehensive Epilepsy Program status: NOT_YET_RECRUITING city: Boston state: Massachusetts zip: 02215 country: United States name: Jennifer Sabbagh role: CONTACT phone: 617-975-8545 email: jsabbagh@bidmc.harvard.edu name: Bernard Chang, M.D., M.M.Sc. role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Cincinnati Children's Hospital Comprehensive Epilepsy Center (CCHMC) status: NOT_YET_RECRUITING city: Cincinnati state: Ohio zip: 45229 country: United States name: Naima Griffin role: CONTACT phone: 513-636-9933 email: naima.griffin@cchmc.org name: Katie Holland role: PRINCIPAL_INVESTIGATOR lat: 39.12713 lon: -84.51435 facility: University of Cincinnati Gardner Neuroscience Institute Epilepsy Center status: NOT_YET_RECRUITING city: Cincinnati state: Ohio zip: 45267 country: United States name: Lucy Mendoza, CCRP role: CONTACT phone: 513-558-3020 email: mendozlc@UCMAIL.UC.EDU name: David Ficker, MD role: PRINCIPAL_INVESTIGATOR lat: 39.12713 lon: -84.51435 facility: Penn State Hershey status: NOT_YET_RECRUITING city: Hershey state: Pennsylvania zip: 17033 country: United States name: Jessica Beiler, MPH,CCRC role: CONTACT phone: 717-531-5656 email: jbeiler@pennstatehealth.psu.edu name: William Trescher, MD role: PRINCIPAL_INVESTIGATOR lat: 40.28592 lon: -76.65025 facility: Children's Hospital of Philadelphia (CHOP) status: NOT_YET_RECRUITING city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Nicholas Abend role: CONTACT email: abend@email.chop.edu name: Nicholas Abend, MD, MSCE role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 facility: UT Southwestern Children's Dallas status: RECRUITING city: Dallas state: Texas zip: 75063 country: United States name: Bonnie Jenkins, LCSW role: CONTACT phone: 214-456-0614 email: bonnie.jenkins@childrens.com name: Deepa Sirsi, MD role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
|
<|newrecord|> nctId: NCT06265090 id: F.P.T 2307017 briefTitle: Effect of Lumbar Stabilization Exercises Combined With Ball and Balloon Exercise in Treatment of Chronic Non-specific Low Back Pain overallStatus: COMPLETED date: 2022-01-10 date: 2022-12-20 date: 2023-01-10 date: 2024-02-20 date: 2024-02-20 name: Delta University for Science and Technology class: OTHER briefSummary: \[Background\] Low back pain occurs when a poor lifestyle weakens the muscular strength of the waist and excessive loads on and tensions of the muscles create pain. Mediating muscle weakening to stabilize the trunk is an important aspect in the recovery of body function in patients with LBP \[Purpose\], this study was conducted to investigate the effect of core stability exercises combined with ball and balloon exercises on chronic non-specific low back pain. \[Subjects and Methods\] a sixty patient of chronic non-specific low back pain were randomly assigned into two groups, group (A) received core stability exercises combined with ball and balloon exercises and group (B) received core stability exercises, these exercises were performed for three times a week for four weeks. Pain was assessed by visual analogue scale (VAS). Spinal function was measured by Arabic Oswestery Disability Index (AODI) and pulmonary function was assessed by pulmonary function test including forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), FEV1/FVC, maximum voluntary ventilation (MVV) and peak expiratory flow (PEF) before and after the study.
|
Keywords: core stability exercises, ball and balloon exercises, chronic non-specific low back pain conditions: Chronic Mechanical Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This randomized controlled experimental trial was carried out at the outpatient clinic of faculty of physical therapy, Delta University for science and technology from April 2023 to October 2023. The aims of the study and the study protocol were explained for each patient before participation in the study. All patients signed an approved informed consent form for participation in this study. Before starting the treatment program, a complete history and physical examination will be taken for all patients.
|
Subjects:
|
Seventy male and female physiotherapy students have chronic non-specific low back pain will be chosen from faculty of physical therapy, delta university for science and technology.
|
The local ethics committee approved this study (Delta University for science and technology, faculty of Physical Therapy, Ethics committee F.P.T 2307017). primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: the participants were selected randomly without their knowledge about in experimental or control group the assessor was for assessment only and the therapist was for treatment only whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 60 type: ACTUAL name: therapeutic exercises name: exercises measure: visual analogue score measure: forced expiratory volume in the first second (FEV1) in liters measure: forced vital capacity (FVC) in liters measure: FVC/FEV1 ratio measure: maximum voluntary ventilation (MVV) measure: peak expiratory flow (PEF) in liter/min measure: Arabic Oswestery Disability Index (AODI) for functional assessment measure: weight measure: age measure: height sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Delta University For Science and Technology city: Al Manşūrah state: Gamasah zip: 11152 country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
|
<|newrecord|> nctId: NCT06265077 id: 2023-199 briefTitle: Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-08 date: 2024-08 date: 2024-02-20 date: 2024-02-20 name: Noha Mansour class: OTHER briefSummary: No randomized controlled trial evaluated the safety and efficacy of double blockade on G-CSF induced bone pain. Therefore, this study aims to evaluate the efficacy and safety of double blockade on the incidence and severity of G-CSF induced bone pain. conditions: Breast Cancer conditions: Filgrastim Adverse Reaction studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: Placebo name: famotidine and loratadine measure: The incidence of grade 2 or 3 bone pain in cycle 1 according to Common Terminology Criteria for Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06265064 id: KhonKaenUniversity briefTitle: STOP-Bang Score and Factors Predicting Difficult Intubation for Prediction of Difficult Mask Ventilation in Obese Patients overallStatus: COMPLETED date: 2022-07-11 date: 2023-10-31 date: 2023-10-31 date: 2024-02-20 date: 2024-02-20 name: Khon Kaen University class: OTHER briefSummary: The goal of this prospective observational study is to test combination of STOP-Bang score and factors predicting difficult intubation can improve accuracy of prediction difficult mask ventilation in obese patients that undergoing to elective surgery under general anesthesia.
|
The main question\[s\] it aims to answer are:
|
* Can combination of STOP-Bang score and factors predicting difficult intubation improve accuracy of prediction difficult mask ventilation in obese patients?
|
* Study about complication after endotracheal tube insertion in obese patients that undergoing to elective surgery under general anesthesia.
|
Participants who undergoing to elective surgery under general anesthesia will
|
* Routine preoperative evaluation and ask about STOP bang questions, evaluate neck circumference, Mallampati grade,Thyromental distance (That routine physical examination for anesthetic care pre-operation)
|
* In operation room, patients will be inducted anesthesia by anesthesiologist (step routine for general anesthesia),observe difficult mask ventilation grading before intubate endotracheal tube and complication after endotracheal tube insertion.
|
If there is a comparison group:
|
Researchers will compare obese patients with/without high STOP bang score \>=3 point plus factor predicting difficult intubation (Mallampati grade 3-4, Neck circumference \> 42 cm, Thyromental distance \< 6 cm)to prediction difficult mask ventilation conditions: Obesity conditions: OSA studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 278 type: ACTUAL name: STOP-Bang score >= 3 with factors predicting difficult intubation measure: Difficult mask ventilation measure: Resipiratory complication sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: KhonKaen University city: Nai Muang state: Khonkaen zip: +66 country: Thailand lat: 15.17901 lon: 100.1282 hasResults: False
|
<|newrecord|> nctId: NCT06265051 id: 100939 briefTitle: Tirofiban After Successful MT Recanalization in AIS acronym: ATTRACTION overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-03-01 date: 2027-09-01 date: 2024-02-20 date: 2024-04-02 name: Xiang Luo class: OTHER name: Wuhan Central Hospital name: Wuhan University name: Renmin Hospital of Wuhan University name: Second Affiliated Hospital of Soochow University name: The First Affiliated Hospital of Zhengzhou University name: Wuhan Hospital of Traditional Chinese Medicine name: The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture name: Huangshi Central Hospital, China name: The First Affiliated Hospital of Yangtze University name: The Fifth Hospital of Wuhan name: Wuhan Puren Hospital name: Xiangyang No.1 People's Hospital name: Xianning Central Hospital name: Wuhan Hanyang Hospital name: Wuhan Third Hospital name: Yichang Central People's Hospital name: Affiliated Hospital of Chengde Medical University name: Beijing Tiantan Hospital name: Nanyang Central Hospital name: Jingzhou Central Hospital name: Taihe Hospital name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School briefSummary: Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset. conditions: Acute Ischemic Stroke conditions: Vessel Occlusion studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1360 type: ESTIMATED name: Tirofiban name: Saline placebo measure: Proportion of patients functionally independent (mRS score 0 to 2) at 90 days measure: Number of participants with symptomatic intracranial hemorrhage measure: Modified ranking scale (mRS) measure: Proportion of patients non-disabled (mRS score 0 to 1) or return to pre-morbid mRS score at 90 days (for patients with mRS > 1) measure: Proportion of patients ambulatory or bodily needs-capable or better (mRS score 0 to 3) measure: Number of participants with improvement of neurological function measure: Health-related quality of life, assessed with the European Quality Five Dimensions Five Level scale (EQ-5D-5L) measure: All-cause mortality measure: Proportion of intracranial hemorrhage of any type sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06265038 id: SANAT-CAGE-2022 briefTitle: Confirmatory Investigation to Evaluate the Performance and Safety of ReSpace TiCell Cage Implants in TLIF overallStatus: RECRUITING date: 2024-02-01 date: 2026-02-01 date: 2026-10-01 date: 2024-02-20 date: 2024-02-21 name: Sanatmetal Orthopaedic and Traumatologic Equipment Manufacturer Ltd. class: INDUSTRY briefSummary: The primary objective of this study is to confirm superiority for the efficacy of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion compared to state-of-the-art.
|
The secondary objective of the study is to evaluate further efficacy and safety of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion with the following secondary efficacy and safety objectives:
|
* To evaluate if implantation causes significant reduction in patient's back, hip/buttock, and leg pain.
|
* To evaluate if implantation causes significant increase quality of life of the patients.
|
* To evaluate if using the device can be considered as safe overall. conditions: Degenerative Instability conditions: Spondylolisthesis conditions: Post-discectomy Syndrome conditions: Post-traumatic Instability studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, single-arm, open-label clinical trial. This clinical investigation addresses to collect data on clinical performance, effectiveness and safety of Sanatmetál's ReSpace TiCell Cage in human subjects following the good clinical practice according to the Medical Device Regulation (MDR) \& EN ISO 14155:2020. The study is conducted in Hungary at National Center for Spinal Disorders. primaryPurpose: OTHER masking: NONE count: 99 type: ESTIMATED name: ReSpace TiCell Cage measure: CT imaging_1 - cumulative fusion rate measure: CT imaging_2 - fusion status measure: Visual Analog Scale measure: Oswestry Disability Index (ODI) measure: AE and ADE measure: Complications measure: Surgical revisions sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Center for Spinal Disorders status: RECRUITING city: Budapest state: Pest zip: 1126 country: Hungary name: Aron Lazary, MD, PhD role: CONTACT phone: +36118877900 phoneExt: 5671 email: lazary.aron@gmail.com lat: 47.49801 lon: 19.03991 hasResults: False
|
<|newrecord|> nctId: NCT06265025 id: GM103-CT-101 briefTitle: GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors overallStatus: RECRUITING date: 2024-02-20 date: 2025-05-30 date: 2028-10-30 date: 2024-02-20 date: 2024-03-21 name: GeneMedicine Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include: conditions: Head and Neck Cancer conditions: Malignant Melanoma conditions: Colorectal Cancer conditions: Renal Cell Carcinoma conditions: Cervical Cancer conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Dose escalation and dose expansion primaryPurpose: TREATMENT masking: NONE count: 125 type: ESTIMATED name: GM103 (Part A) name: GM103 (Part B) name: GM103 and Pembrolizumab (Part C) measure: Percentage of patients with DLTs by cohorts measure: Percentage of patients with DLTs measure: Incidence of AEs, AESIs, SAEs, AEs leading to discontinuation, and AEs resulting in death measure: ORR measure: DCR defined as the proportion of patients whose BOR was CR, PR and SD measure: Median PFS defined as the time from the date of the first administration of study drug to the date of disease progression or death measure: Incidence of GM103 detection measure: Changes in the level of anti-adenovirus antibodies(ADA) in blood compared to baseline (ADA in genome copies/mL using qPCR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Center status: NOT_YET_RECRUITING city: Goyang-si state: Gyeonggi-do zip: 10408 country: Korea, Republic of name: WY Choi role: CONTACT lat: 37.65639 lon: 126.835 facility: Korea University Anam Hospital status: NOT_YET_RECRUITING city: Seoul zip: 02841 country: Korea, Republic of name: SH Lee role: CONTACT lat: 37.566 lon: 126.9784 facility: Hanyang University Seoul Hospital status: NOT_YET_RECRUITING city: Seoul zip: 04763 country: Korea, Republic of name: MS Chung role: CONTACT lat: 37.566 lon: 126.9784 facility: Severance Hospital, Yonsei University Health System status: RECRUITING city: Seoul country: Korea, Republic of name: JY Lee role: CONTACT lat: 37.566 lon: 126.9784 hasResults: False
|
<|newrecord|> nctId: NCT06265012 id: PHV01-C-101 briefTitle: Study to Evaluate the Recombinant Vesicular Stomatitis Virus (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects acronym: PHV01 overallStatus: RECRUITING date: 2024-02-05 date: 2024-04-17 date: 2024-09-16 date: 2024-02-20 date: 2024-02-22 name: Public Health Vaccines LLC class: INDUSTRY name: Biomedical Advanced Research and Development Authority briefSummary: This is a Phase 1 randomized, single-blind, placebo-controlled, ascending dose study to evaluate the safety and immunogenicity of rVSV∆G-MARV-GP \[Angola\] (PHV01, Marburg Virus glycoprotein \[MARV GP\] Vaccine) in healthy adults. PHV01 is a live, attenuated rVSV vaccine expressing the MARV GP. The main questions it aims to answer are:
|
* Which dose of PHV01 is safe to administer to, and well-tolerated by healthy adult subjects?
|
* What is the immunologic response (Marburg-specific Immunoglobulin G (IgG) ELISA antibody and neutralizing antibodies) to each dose level?
|
Participants will receive 1 intramuscular injection of PHV01 or placebo on Day 1 and will be followed for 181 days. conditions: Marburg Virus Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Single-blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: PHV01 name: Placebo measure: Solicited Adverse Events (AEs) measure: Unsolicited AEs measure: Other AEs measure: Immunogenicity, Antibodies (Ab) measure: Immunogenicity, Neutralizing antibodies (NEUT) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: CenExel RCA status: RECRUITING city: Hollywood state: Florida zip: 33024 country: United States name: Terry Piedra role: CONTACT phone: 305-596-3125 email: t.piedra@cenexel.com name: Amanda Gonzalez role: CONTACT phone: 813-817-7984 email: amanda.gonzalez@cenexel.com name: Craig Shapiro, MD role: PRINCIPAL_INVESTIGATOR lat: 26.0112 lon: -80.14949 hasResults: False
|
<|newrecord|> nctId: NCT06264999 id: 427976 briefTitle: Robotic Assisted Knee Arthroplasty - Retain the Anterior Cruciate Ligament or Not overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-04 date: 2026-04 date: 2024-02-20 date: 2024-02-23 name: St. Olavs Hospital class: OTHER name: Smith & Nephew, Inc. briefSummary: The goal of this clinical trial is to compare the function of the knee after retaining or sacrificing the anterior cruciate ligament in robotic assisted knee arthroplasty.
|
The main questions it aims to answer are:
|
Does retaining the anterior cruciate ligament improve postoperative gait? Participants will perform
|
* Gait analysis
|
* Stair performance test
|
* CT based Micromotion analysis of the implant micromovement conditions: Arthritis Knee conditions: Arthroplasty conditions: Gait Analysis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Journey II CR name: Journey II XR measure: Preferred walking speed (meter/minute) after surgery measure: CT-RSA measured maximum total point of motion(MTPM) measure: evaluation of max walking speed(m/minute) measure: stride length(cm) measure: step length in mid stance phase (cm) measure: single leg support time(s) measure: double-leg support time(s) measure: stair performance(s) measure: Rating pain using NRS (Numeric Rating Scale). measure: KOOS-PS (Knee Injury and Osteoarthritis Outcome score) measure: Clinical evaluation of range of motion . measure: Rating outcome using EQ-5D-5L(European quality of life index version 5D-5L), measure: IKSS (International Knee Society System knee and function score) measure: FJS-12 (Forgotten Joint score) measure: Clinical evaluation of Anteroposterior stability. measure: Clinical evaluation of Mediolateral stability. measure: A long leg X-Ray identifying outliers with Hip Knee Ankle angle Varus <-3 ºor Valgus >3 º measure: Presence of eminence fractures sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St.Olavs Hospital city: Trondheim state: Trøndelag zip: 7006 country: Norway name: Anders Sjøstrøm, MD role: CONTACT phone: +4772575241 email: anders.sjostrom@stolav.no name: Siri Bjørgen Winther, PhD role: SUB_INVESTIGATOR name: Sølvi Liabekk Selli role: SUB_INVESTIGATOR lat: 63.43049 lon: 10.39506 hasResults: False
|
<|newrecord|> nctId: NCT06264986 id: 2023-09-02 briefTitle: The Effects of Ashwagandha (Withania Somnifera) Supplementation on Exercise Performance in Female Footballers overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-13 date: 2024-02-21 date: 2024-02-21 date: 2024-02-20 date: 2024-02-20 name: Blanca Roman-Viñas, MD class: OTHER briefSummary: The goal of this clinical trial is to evaluate the effects of short-term root extract ashwagandha supplementation on exercise performance in female footballers. The main question it aims to answer are:
|
Will short-term supplementation of root extract ashwagandha improve muscle strength markers in female footballers? Will short-term supplementation of root extract ashwagandha improve perception of recovery following high-intensity exercise in female footballers?
|
Participants will either supplement 600mg (5% withanolides) root extract ashwagandha or placebo once a day for 28 days. There will be three data points: baseline, 14 days and 28 days. Researchers will compare values of intervention against placebo to see if there is an effect on muscle strength or perception of recovery. conditions: Muscle Strength studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double-blind, placebo-controlled, randomised trial primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 30 type: ACTUAL name: Ashwagandha name: Placebo measure: Increased lower body muscle strength measure: Increased maximum voluntary muscle strength measure: Increased upper body muscle strength and explosiveness measure: Improved overall muscle strength measure: Improved perception of wellbeing measure: Improved perception of recovery sex: FEMALE minimumAge: 17 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Club Esportiu Seagull city: Badalona state: Barcelona zip: 08917 country: Spain lat: 41.45004 lon: 2.24741 hasResults: False
|
<|newrecord|> nctId: NCT06264973 id: NL9318 briefTitle: Maternal and Fetal/Neonatal Pharmacokinetics and - Dynamics of Corticosteroids During Pregnancy acronym: MaDyCo overallStatus: RECRUITING date: 2021-01-01 date: 2025-06-01 date: 2025-12-01 date: 2024-02-20 date: 2024-02-20 name: Erasmus Medical Center class: OTHER briefSummary: Improving pregnancy outcome is essential in improving health of both parents and their offspring during the life course. Preterm birth (PTB) occurs in 10-15% of all pregnancies, is the leading cause of perinatal mortality and morbidity {Goldenberg, 2008}, has long-term adverse consequences for postnatal health {Huddy, 2001} and is a burden for health care expenditure. In order to improve neonatal outcome, antenatal corticosteroids (ACS) are routinely administered to women at risk for preterm delivery before 34 weeks of pregnancy. {Jobe, 2018;Roberts, 2017;Travers, 2018} However, the current, worldwide standard of care, for the use of ACS is still based on animal experiments performed in the 1970's. {Liggins, 1969} Although ACS treatment to improve neonatal outcome was clinically introduced in the 70's, still only two dosing regimens are used, neither of which have been investigated, re-evaluated or refined to determine the optimal doses or treatment interval. With the current health care approach of personalized medicine in mind, the same universal approach for everybody, independent of gestational age, number of fetus, maternal weight or comorbidity one dose does not fit all since it often has not the desired effect. Due to the lack of optimization of the above mentioned synthetic corticosteroid drug regimens {Kemp, 2019}, significant gaps in knowledge exist. An important aspect to set up, investigate and understand dosing and also dosing interval experiments, is knowledge of the maternal individual pharmacokinetics and pharmacogenetics of the drug of interest during pregnancy. conditions: Preterm Birth studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Pharmacokinetics of antenatal corticosteroids by investigation of betamethasone concentrations in serum measure: Maternal age measure: Fetal sex measure: Maternal weight/BMI measure: Number of fetus measure: Parity: the number of times a woman has given birth to a live neonate (any gestation) or at 24 weeks or more measure: PE by urine measurement of protein-creatinine ratio measure: Oestradiol concentration in serum measure: Cord blood and neonatal blood measure: CYP3A4 level sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus Medical Center status: RECRUITING city: Rotterdam state: Zuid Holland zip: 3015GD country: Netherlands name: Sam Schoenmakers, MD, PhD role: CONTACT phone: +31107037439 email: s.schoenmakers@erasmusmc.nl name: Emma Ronde-Salminen, MD role: CONTACT phone: 0031683997312 email: e.ronde@erasmusmc.nl lat: 51.9225 lon: 4.47917 hasResults: False
|
<|newrecord|> nctId: NCT06264960 id: E10208771 briefTitle: The Effect of Music Therapy and Breathing Exercise on Anxiety and Pain in Patients Undergoing Coronary Angiography overallStatus: COMPLETED date: 2022-09-15 date: 2023-05-30 date: 2023-10-02 date: 2024-02-20 date: 2024-02-20 name: Ulku Gunes class: OTHER briefSummary: Coronary angiography serves as the primary diagnostic technique for cardiovascular disease. However, this invasive procedure commonly triggers pain, anxiety, and fear in patients. The objective of this randomized controlled trial was to examine the impact of music and breathing exercises on anxiety and pain levels in individuals undergoing coronary angiography. The study, conducted as a single-blind, randomized controlled trial, involved a sample of 165 patients, with 55 in each group: the control group, the breathing exercise group, and the music therapy group. Patients in the music group listened to music during angiography, those in the breathing exercise group practiced exercises 30 minutes before the procedure, while the control group received standard treatment. Anxiety levels were assessed both before and after the procedure, and pain levels were measured post-procedure. The study strictly adhered to the CONSORT statement guidelines. conditions: Procedural Pain conditions: Procedural Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This single-center, single-blind, randomized controlled trial was conducted in Izmir, Turkey, from July 2021 to July 2022. Participants were randomly assigned to one of three groups: intervention 1 (music), intervention 2 (breathing exercises), or control (standard care), in a 1:1:1 ratio. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The nurse responsible for conducting all measurements, including pain and anxiety assessments using the Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI), was not part of the research team.
|
The nurse, being independent and not aware of the participants' group assignments, helps to ensure that the assessments are conducted impartially, without knowledge of which intervention each participant received. whoMasked: OUTCOMES_ASSESSOR count: 512 type: ACTUAL name: Music therapy name: Breathing exercise measure: State-Trait Anxiety Inventory measure: Visual Analog Scale sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ege University city: Bornova state: İzmir zip: 35100 country: Turkey lat: 38.47921 lon: 27.2399 facility: Ülkü Güneş city: Bornova state: İzmir zip: 35100 country: Turkey lat: 38.47921 lon: 27.2399 hasResults: False
|
<|newrecord|> nctId: NCT06264947 id: CMUH112-REC2-141 briefTitle: Efficacy of Laser Acupuncture on Zanzhu (BL02) for Dry Age-related Macular Degeneration overallStatus: ENROLLING_BY_INVITATION date: 2024-01-26 date: 2024-11-01 date: 2024-11-01 date: 2024-02-20 date: 2024-02-20 name: China Medical University Hospital class: OTHER briefSummary: This study is to see if laser acupuncture is a better way to treat dry-AMD (Age-related Macular Degeneration) compared to sham laser acupuncture, in the aspect of visual acuity. Investigators planed to recruit participants who are diagnosed with dry-AMD, and not younger than 20 years old. Before the study, investigators will measure the participants' BCVA (Best Corrected Visual Acuity), and then practice laser acupuncture and sham-laser acupuncture on experiment group and control group respectively. After the 4-week study, investigators will measure the participants' BCVA again. conditions: Age-related Macular Degeneration studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: laser acupuncture name: sham laser acupuncture measure: BCVA (Best Corrected Visual Acuity) sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China Medical University Hospital city: Taichung zip: 404 country: Taiwan lat: 24.1469 lon: 120.6839 hasResults: False
|
<|newrecord|> nctId: NCT06264934 id: DiCECT briefTitle: An Investigation Into Dielectric Assessment of Permittivity and Cancer in Human Using a Novel Electrical Capacitance Tomography Scanner acronym: DiCECT overallStatus: RECRUITING date: 2024-01-25 date: 2024-12 date: 2024-12 date: 2024-02-20 date: 2024-02-23 name: Zedsen Limited class: INDUSTRY name: Imperial College Healthcare NHS Trust briefSummary: The goal of this observational study is to investigate the ability of a the Z-scanner to identify and differentiate cancer and benign lesions from healthy breast tissue based on permittivity. The main questions it aims to answer are:
|
1. Determine the permittivity values of the Z-scanner associated with healthy, benign, and malignant tissue in human breasts.
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.